Novartis unveils investigation of infant's death in European Zolgensma trial

22nd April 2019 Uncategorised 0

On the cusp of Zolgensma’s landmark FDA approval, Novartis has big hopes for the first-ever gene therapy for spinal muscular atrophy. But a patient’s death in the treatment’s European trial could throw a wrench into its plans.

More: Novartis unveils investigation of infant's death in European Zolgensma trial
Source: fierce